Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...

Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from ...

Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...

Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...

Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...

First, we continue to advance our novel TNFR2 agonist antibody program, NKTR-0165. IND-enabling studies are ongoing with the goal of preparing for an IND submission in the second half of 2025.